FDA News

FDA Approves Alpharma's KADIAN New 10mg Strength

(April 23, 2007)-- Alpharma, a global specialty pharmaceutical company, today announced that it has been notified by the United States Food and Drug Administration("FDA") that its pending application for KADIAN(R) 10mg strength capsule has received approval.

The company expects to launch this new dosage strength in 2007. This is the second FDA approval for a KADIAN line extension in 2007. In March 2007, the company received FDA approval for a 200mg dosage strength which was launched in April 2007. KADIAN is Alpharma's branded extended release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strengths. KADIAN's wide range of dosage strengths is intended to assist in physicians' efforts to individualize their patient's treatments by offering more choices in managing their pain.

"We are pleased to be able to offer a wide array of KADIAN dosage strengths to physicians and their patients. We will now have the broadest range of dosage strengths in the long-acting opioid market," commented Dr. Ronald Warner, President of Alpharma's Pharmaceuticals business. "This comprehensive product offering, along with KADIAN's ability to be administered by several routes, provides physicians with considerable flexibility as they select effective solutions to treat their patients' pain."

Share or bookmarklet this web page at: